Jessica Merrill

Jessica Merrill

Senior Editor

Brooklyn, NY

Jessica is a senior editor, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues.

Latest from Jessica Merrill

Scholar Rock Shows Muscle-Building PoC In Obesity

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Supernus Secures Sage With CVR-Supported Deal

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.

ACIP Upheaval Leaves Merck & Co. In A Lurch

Merck’s newly approved Enflonsia for RSV is one of the products expected to be recommended for use by the CDC Advisory Committee on Immunization Practices later this month.

With ACIP Upheaval, Merck & Co. Among Those Left In A Lurch

Merck’s newly approved Enflonsia for RSV is one of the products that was expected to be recommended for use by the CDC advisory committee in June.